Alembic

Alembic has announced the acquisition of an Active Pharmaceutical
Ingredients (API) manufacturing facility of Nirayu for Rs 17.50 crore.
It is a US FDA approvable facility. The acquired unit is located near
Vadodara and will be used by Alembic to increase its API business and
regulatory filings. This acquisition is on a going concern basis
together with the assets (including all rights, privileges, and
benefits of use and exploitation of designs and full power and
authority in respect of the technology, know-how, licenses,
franchises, business and marketing information, current assets and
continuing employees etc) and liabilities on the effective date. CRAMS
is the growth opportunity that the company is actively pursuing.
Alembic is looking at increasing its revenues from the international
markets.